Most patients with bipolar disorder (BD) are not engaged in specialty mental health care despite the clinical complexity and risk of selfharm (Wang, Lane, et al., 2005) . The prevalence of BD is relatively high in primary care settings (Cerimele, Chwastiak, Dodson, & Katon, 2014) , where a quarter of those patients who screen positive for depression or are prescribed antidepressants also screen positive for BD (Hirschfeld, Cass, Holt, & Carlson, 2005; Olfson et al., 2005) . Accurate recognition of BD occurs infrequently in this setting , and even among those eventually diagnosed, an average of 6 -8 years elapses between onset and diagnosis (Lish, Dime-Meenan, Whybrow, Price, & Hirschfeld, 1994; Wang, Berglund, et al., 2005) . Detection is complicated by the relative infrequency of manic episodes compared to depressive episodes and because primary care patients typically present during a depressive or mixed episode (Hirschfeld, 2001; Strakowski, 2007) . Because the most common misdiagnosis for BD is unipolar depression (Hirschfeld, Lewis, & Vornik, 2003) , there is substantial risk that patients with unrecognized BD will receive antidepressant monotherapy , which practice guidelines advise against because of the risk of inducing a manic episode (Pacchiarotti et al., 2013 ). Yet, antidepressant monotherapy is common in this setting (Ghaemi et al., 2006) , with 71%Ϫ73% of patients with BD receiving inappropriate medication, and another 18% receiving no psychotropic medication (Merikangas et al., 2007; Olfson et al., 2005) . Given the negative consequences of misdiagnosing BD as depression, the importance of detecting and treating BD in primary care is increasingly being recognized (Cerimele, Chwastiak, Chan, Harrison, & Unützer, 2013; Kilbourne et al., 2010; Kilbourne, Goodrich, O'Donnell, & Miller, 2012; Lewis, 2004; Manning, Ahmed, McGuire, & Hay, 2002; Swann et al., 2005) .
Federally Qualified Health Centers (FQHCs) provide services to 26 million patients living in rural and inner-city areas (Health Resources & Services Administration, 2017) , where they represent the de facto mental health system for disadvantaged populations (Fox, Merwin, & Blank, 1995; Geller & Muus, 1997) . Mental health prevalence rates are higher in FQHCs than in private practice (Burke et al., 2013) . Evidence-based practices (EBPs) for BD are typically designed and tested in large specialtyϪmulti-specialty clinics and are not feasible to implement in FQHCs that typically lack on-site psychiatrists or psychologists. Moreover, the findings from randomized trials that constitute the evidence base for BD treatments are not necessarily generalizable to FQHCs serving disadvantaged populations (Bowden et al., 2012) . Local practice-based evidence about the effectiveness of adapted EBPs is expected to foster sustainability of adoption (Hohmann & Shear, 2002) .
We report here on the results of an Academic Community Implementation Partnership (ACIP) that focused on the identification, adaptation, implementation, and evaluation of EBPs for BD (Hunt et al., 2012) . The partnership was between the University of Arkansas for Medical Sciences, the Community Health Centers of Arkansas, and six Arkansas FQHCs (see Table 1 ). The ACIP Steering Committee guided implementation and evaluation efforts. BD was chosen by health care providers from participating FQHCs based on their difficulties managing patients with this disorder. The six FQHCs exhibited considerable variation in organizational culture and climate (Glisson et al., 2008; Kramer, Drummond, Curran, & Fortney, 2017) .
Quality improvement efforts within individual or small numbers of practices are often used to bring about changes in care delivery but with varying success. Implementing significant practice changes (i.e., practice transformation) requires sustained investment in time and resources . A wide range of implementation strategies designed to promote the adoption of EBPs can be used (Powell et al., 2015) . These implementation efforts generally involve a team of individuals representing the distinct areas affected by the change (e.g., nursing, information technology) working with a clinical "champion" who serves to direct and support the work of the team. Implementation facilitators external to the organization can also work with practices on problem identification and resolution and to provide support and encouragement Stetler et al., 2006) . Another critical component is the identification of metrics to assess progress and guide course corrections (Berwick, 1998; Young, Roberts, & Holden, 2017) . The iterative nature of the quality improvement processes allows for tailoring the EBP to the needs and capacities of particular settings.
Method
Before initiating the implementation of EBPs for BD, each of the participating FQHCs implemented the evidence-based telepsychiatry collaborative care model for depression (Fortney (Bauer et al., 2011; Meredith et al., 2006; Unützer et al., 2012) .
Implementation Strategies
We used an external facilitation method known as evidence-based quality improvement (EBQI; Rubenstein, Mittman, Yano, & Mulrow, 2000; Rubenstein et al., 2002) . In EBQI, both researchers and clinic staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts (Parker, de Pillis, Altschuler, Rubenstein, & Meredith, 2007; Rubenstein et al., 2002) . Although emphasizing the involvement of outside experts and empirical evidence, EBQI stresses that a health care organization's own staff are best positioned to improve care. Local staff contributed the knowledge needed to tailor the EBP for their own particular needs and organizational capabilities. Researchers contributed knowledge about the EBPs and implementation best practices.
The EBQI process (see Figure 1 ) began with a needs assessment that involved PCPs' completing a brief anonymous survey about their experience and comfort diagnosing and prescribing for depression and BD. Qualitative interviews were also conducted with providers and patients. Initial discussions indicated that PCPs had difficulty distinguishing between BD and unipolar treatment-resistant depression (TRD), so both types of disorders were targeted by the EBQI process. Interviews focused on screening, diagnosing, and managing BD and TRD. Barriers and facilitators to managing these disorders, along with clinical processes that were perceived to need changing, were assessed. Interviews were audio-recorded and notes taken. Relying primarily on the notes (using audio recordings for clarification), we conducted rapid content analysis to make results available quickly to the EBQI team (Sobo, 2005; Sobo, Simmes, Landsverk, & Kurtin, 2003) .
The EBQI team included a clinician from each FQHC, two FQHC patients with BD, two researchers, and two clinical content experts. The EBQI team had seven conference calls in 3 months. Topics discussed included needs assessment findings, screeners for BD, screener workflow, defining and identifying TRD, telepsychiatric consultation, medication provider guidelines and patient handouts, internetdelivered psychotherapy, online peer support, Figure 1 . Evidence-based quality improvement process. See the online article for the color version of this figure. and implementation strategies. The role of the content experts and researchers was to ensure that chosen practices were evidence-based and that adaptations did not eliminate core treatment elements. FQHC clinicians were responsible for tailoring the EBP to meet the needs, preferences, and resources of their clinic and to minimize staff burden. Patients were responsible for ensuring that adapted EBPs were acceptable. A qualitative researcher monitored the calls for participation and provided feedback about equity to the researchers.
Once the EBPs were chosen and adapted, an implementation template was developed by the EBQI team. For each EBP, this template specified (a) the clinical objective, (b) action steps, (c) staff responsibilities, (d) how success is evaluated, (e) resources available and needed, (f) communications plan, and (g) potential barriers and solutions. Each FQHC organization chose one clinic for implementation and an implementation champion, who was a senior clinician in a leadership position. Researchers provided external facilitation.
Evaluation
The evaluation focused on the RE-AIM constructs: reach, efficacy, adoption, implementation fidelity, and maintenance (Glasgow, Vogt, & Boles, 1999) . To develop internal capacity among FQHCs to conduct their own evaluations, we mentored FQHC staff to collect their own data. The goal of the evaluation was to provide FQHCs with local evidence that the adapted EBPs were effective. Because we did not want to burden FQHC staff with data collection activities, we used a telephone-based interactive voice response (IVR) system to call patients directly and collect patient-reported outcomes. IVR-administered psychiatric assessments are reliable and valid (Mundt et al., 2006) . The system included a web portal for FQHC staff to add contact information for consenting patients and download survey data in spreadsheet format. The IVR system required patients to call a toll-free number and enter an ID to verify authentication. Three months after completing the baseline assessment, patients received up to three texts or audio messages reminding them to call back into the IVR system and complete the follow-up assessment.
At baseline, the IVR system asked about demographics, depression symptoms using the nine-item Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer, & Williams, 2001) , and manic symptoms using the five-item Altman Mania Rating Scale modified for telephone administration (Altman, Hedeker, Peterson, & Davis, 1997) . The 3-month follow-up assessed clinical outcomes (medication adherence, depression and mania symptoms) and implementation success (use of EBPs). Care managers conducted a brief chart review to measure clinical outcomes (BD screening results, diagnosis), and implementation success (receipt of care management, telepsychiatric consultation, PCPprescribed recommended medications).
The FQHCs submitted a Federalwide Assurance to the Office of Human Research Protection to have the University of Arkansas for Medical Sciences Institutional Review Board, which approved the research, provide oversight.
Results

Needs Assessment
The needs assessment survey was completed by 18 PCPs (75% response rate). For depression, 100% of PCPs reported diagnosing and prescribing and felt "very comfortable" doing so. For BD, 55% of PCPs reported diagnosing and 61% reported prescribing, and those PCPs felt "moderately comfortable" doing so. Qualitative interviews with eight PCPs and six nursing directors indicated consistent annual depression screening using the PHQ-9 but inconsistent methods for detecting or differentiating between TRD and BD. Providers believed that both BD and TRD frequently went undetected and were supportive of systematic screening, though views varied about how to screen for BD and the definition of TRD. Many PCPs felt uncomfortable prescribing medications for BD, and most patients with a suspected diagnosis of BD or TRD were referred to a local community mental health center. However, referrals were often unsuccessful, and PCPs felt obligated but unprepared to treat these patients. Many PCPs were dissatisfied with the communication from their local community mental health center providers. Despite never comanaging their patients with a psychiatrist, PCPs expressed a preference for comanagement and were open to telepsychiatric consultation.
Qualitative interviews with seven patients identified misdiagnosis as a common experience, with BD often being first diagnosed during a psychiatric hospitalization. Patients reported being referred to community mental health centers, but lack of insurance, long wait times, and stigma prevented them from engaging in care. Most patients reported receiving all their mental health treatment in the FQHC and, despite support from care managers, were not satisfied with their care. Patients reported wishing their PCPs had more mental health training and spent more time listening to them. Strong preferences for counseling and peer support were common themes. Receiving mental health services in the FQHC setting via interactive video was reported as being acceptable.
Evidence-Based Practices and Adaptations
The EBQI team chose five EBPs: (a) screening for BD, (b) telepsychiatric consultation, (c) mood stabilizer prescribing guidelines, (d) internet-delivered cognitive behavioral therapy, and (e) online peer support. Two hours of Continuing Medical Education credit was provided to FQHC staff via webinar. The first educational session focused on diagnosing and prescribing for BD and TRD. The second session focused on telepsychiatric consultation, cognitive behavioral therapy, and peer support.
The EBQI team chose to screen for BD using the Composite International Diagnostic Interview (CIDI) because it is a staged screener that reduces administration burden (Kessler et al., 2006) . The EBQI team considered whether to screen all patients or to subgroups of patients with higher prevalence rates of BD, for example, patients screening positive for depression, patients diagnosed with depression (Gill, Chen, Grimes, & Klinkman, 2012) , patients prescribed antidepressants, and patients failing two antidepressant trials. Screening just those at high risk for BD lowers screening burden and minimizes false positives but may delay or prevent recognition for some patients. To balance these competing concerns, the EBQI team decided to screen patients for BD after a positive annual depression screen. We contracted with the electronic health record vendor to develop a screening template that automatically launched after a positive annual PHQ-9 screen. TRD was defined as two failed adequate antidepressant trials in which medication adherence and treatment nonresponse (Ͻ50% decrease in PHQ-9 scores) was verified by the care manager over an 8-week period. Patients meeting BD screening and/or TRD criteria were recruited for the evaluation.
A telepsychiatric consultation referral and a medication algorithm were developed (see Figure 2) . The university installed interactive video equipment in the FQHCs and offered free telepsychiatric consultations. A telepsychiatric consultation protocol that provided instructions for eligibility, scheduling, consenting, information sharing, rooming, and establishing the audiovideo connection was developed. One FQHC moved into a new building at the beginning of the implementation period, and its interactive video equipment was not functional during the duration of the evaluation.
The EBQI team chose five mood stabilizers for the BD prescribing guidelines based on efficacy, side effects, cost, PCP acceptability, and monitoring burden (see Figure 3) . The guidelines specified dosing instructions, advantagesdisadvantages, side effects, drug interactions, and recommended lab tests. In addition, twopage patient educational handouts were developed for each medication.
Based on patients' requests for counseling and peer support, two technology-assisted interventions were chosen. The first was Beating the Blues, a self-administered internet-delivered cognitive behavioral therapy program. Care managers helped the patients set up e-mail accounts (required for login ID), manage passwords, and access the program. In addition, care managers encouraged patients to engage in an online peer support program operated by the Depression and Bipolar Support Alliance. Because most patients lived in rural areas with high stigma levels and perceived lack of treatment anonymity, being able to access these services via the Internet was considered an advantage.
Screening
Implementation fidelity. Outcomes are reported for five of the six FQHCs because one site screened for BD after every positive PHQ-9 rather than per protocol (i.e., only if the annual PHQ-9 was positive). During the 6-month implementation period, there were 2,234 positive annual PHQ-9 screens, and 15% (n ϭ 324) were administered the BD screen. Two of the five FQHCs implemented the CIDI screen with good fidelity (70% and 64% completed after a positive annual PHQ-9), one FHQC implemented with poor fidelity (25%), and two FQHCs implemented with very poor fidelity (3% and 11%). Of all the completed BD screens, 40% (131/324) were classified as high or very high risk.
Effectiveness. The BD screener performed reasonably well. Of those screened (n ϭ 80), patients with higher risk were significantly (p Ͻ .01) more likely to be chart-diagnosed with BD either before or after screening: 17% of very low risk, 33% of low risk, 50% of moderate risk, 67% of high risk, and 69% of very high risk. Because most patients did not have an encounter with the consulting telepsychiatrist for formal diagnosis, the diagnoses cannot be used to accurately assess screening sensitivityϪspecificity. Table 2 reports the characteristics of the patients (n ϭ 104) with BD and TRD who consented to participate in the evaluation. According to chart review, only 14% of the sample had a baseline (prescreening) diagnosis of BD. About half (47%; n ϭ 49) were considered high or very high risk according to the BD screener. About a quarter (23%; n ϭ 24) were not screened for BD, and another 29% (n ϭ 30) were screened but screened negative. Among those not screened or screening negative, 10 (19%) were either diagnosed with BD at baseline or received a new diagnosis during their 3-month follow-up. Summing the screen positives and the diagnosed, 57% (n ϭ 59) of the sample had probable BD. The remaining 43% (n ϭ 45) had TRD. Two thirds (62%; n ϭ 64) of the sample completed the 3-month follow-up IVR survey. The majority (88%) reported they were prescribed psychotropic medications, and 73% of those reported they "never missed a dose" or "missed only a couple of times" in the past 2 weeks.
Patient Characteristics
Diagnosis and Treatment
Reach and adoption. Seventy-five percent of the sample had at least one care manager encounter. About a third (38%) of the sample had a telepsychiatric consultation. Two clinics successfully completed telepsychiatric consultations for the majority of their patients (73% and 83%), whereas half the clinics had no consultations. Overall, 28% received a new diagnosis of BD. Among patients with a telepsychiatric consultation (n ϭ 39), PCPs usually (64%) prescribed the recommended medication. Overall, 24% (n ϭ 25) of the sample were prescribed a medication recommended by the consulting telepsychiatrist, 32% were prescribed a new mood stabilizer, and 28% were prescribed a new antidepressant. Only 13% of those completing the survey reported using Beating the Blues during the previous 3 months, with users completing 1.3 (SD ϭ .9) sessions on average (see Table  3 ). Even fewer (6%) attended an online peer support group, with users attending 2.5 (SD ϭ 1.7) groups on average.
Clinical effectiveness. Baseline PHQ-9 depression scores were moderately severe ( ϭ 17.7, SD ϭ 5.8), and there was a modest ( ϭ Ϫ3.3, SD ϭ 6.5) decrease by 12 weeks. A clinical response (Ն50% decrease in PHQ-9) was observed in 21% of patients (see Table 3 ). The baseline mania scores were low ( ϭ 4.2, SD ϭ 2.7), indicating that on average patients experienced four mania symptoms "occasionally" in the past week. At 12 weeks, there was little change ( ϭ 0.7, SD ϭ 3.5) in mania symptoms.
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Discussion
This article reports the implementation and clinical outcomes of an EBQI effort conducted by six FQHCs, their primary care association, and a state medical school. Five EBPs for detecting and treating BDϪTRD were identified and adapted for FQHCs. For implementation success to be evaluated, this effort also included developing an internal capacity for FQHCs to assess clinical outcomes.
BD screening was implemented with variable success across sites, with one third of FQHCs adopting the screening protocol with good fidelity. The screener performed well, with two thirds of patients with positive screens being diagnosed with BD. Telepsychiatric consultation was also implemented with variable success across sites, with one third of FQHCs suc- ). In the current study, a number of common implementation strategies were used, including a needs assessment, the use of a multiple-stakeholder team to identify and adapt EBPs, local clinical champions, an implementation checklist, and external facilitation. Collectively, these implementation strategies represent a pragmatic approach to practicing transformation in primary care settings. Wide variation in implementation outcomes is commonly observed following real-life quality improvement and is consistent with the widely shared experience that practice change is difficult in safety net settings (Meredith et al., 2006) . Based on our inconsistent implementation outcomes, we recommend several potential modifications to our approach. First, we could have provided more coaching to the local champion at FQHCs, especially at sites with lower organizational culture and climate scores. There is good evidence that external facilitators can coach internal facilitators to promote the adoption of complex interventions at health care systems facing implementation barriers (Kirchner et al., 2014) . Second, we could have used pay-for-performance to encourage adoption. This implementation strategy has been shown to be effective in improving the fidelity of collaborative care in FQHC settings (Unützer et al., 2012) . It also may be that some FHQCs were just not ready to implement these EBPs. One FQHC fully met (and two more almost met) Glisson's (Glisson et al., 2008) criteria for "worst organizational culture" (Kramer et al., 2017, p. 979) , and two of these FQHCs did not successfully adopt any of the EBPs. One highly resource-intensive approach would have been to conduct a preimplementation intervention to improve organizational culture at these FQHCs (Aarons, Ehrhart, Farahnak, & Hurlburt, 2015; Glisson, Dukes, & Green, 2006) .
There are few benchmarks with which to compare the clinical effectiveness observed in these safety net primary care clinics. Whereas 32% of patients were prescribed a new mood stabilizer and another 28% were prescribed a new antidepressant, only 21% experienced a 50% reduction in depression symptoms by 12 weeks. In the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) medication trial, 35% of patients with BD experienced a 50% reduction by 16 weeks (Sachs et al., 2007) . However, the STEP-BD trial enrolled a much higher income and less diverse population, and patients were prescribed medications by psychiatrists in specialty mood clinics at academic medical centers and had access to evidence-based psychotherapy. There has only been one other BD collaborative care study conducted in the FQHC setting (Cerimele, Chan, et al., 2014) . This observational study found that 33% of patients experienced a 50% reduction in depressive symptoms. However, those patients were enrolled in collaborative care for 30 weeks on average, which is substantially longer than our 12-week follow-up. Thus, although the response rate observed in this study was relatively low, this could be due to differences in study characteristics.
Being practice-based and pragmatic, this research had both strengths and limitations. The EBPs were selected by and adapted for the FQHCs and thus were more likely to meet their needs. Where successfully implemented, screening and telepsychiatric consultation were sustained after the evaluation. The EBQI process also generated practice-based evidence that helped the FQHCs identify which EBPs were and were not effective. Limitations included lack of a control group, short follow-up period, limited case mix adjustment, and small sample size. However, from the perspective of the FQHCs, the lack of internal validity is outweighed by the high generalizability of this practice-based evidence to their own patients.
